Healthcare Royalty IPO: How to Buy Healthcare Royalty Stock When It Goes Public

Healthcare Royalty is expected to go public soon. Here's what we know about the IPO — and how to buy Healthcare Royalty stock when it's available.

What we know about the Healthcare Royalty IPO

Healthcare Royalty filed a registration form with the US Securities and Exchange Commission (SEC) to go public on the Nasdaq Global Market under the ticker symbol HCRX. Not yet an official IPO, this is one of the first steps of taking a private company public.

The exact IPO date has not been announced. Stocks are expected to open at a price of between $15.00 and $17.00. We'll update this page with more information as it becomes available.

How to buy Healthcare Royalty stock when it starts trading

Once Healthcare Royalty goes public, you'll need a brokerage account to invest. Consider opening a brokerage account today so you're ready as soon as the stock hits the market.

Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
Open your brokerage account. Complete an application with your details.
Confirm your payment details. Fund your account.
Research the stock. Find the stock by name or ticker symbol – HCRX – and research it before deciding if it's a good investment for you.
Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.

Finder's picks for buying Healthcare Royalty stock when it goes public

Go to site

$0 commission trading
Instant withdrawals with a 1.75% fee
Supports 250+ cryptocurrencies
High-yield account earns up to 4.40% APY

Disclaimer

Go to site

Trade options, futures, options on futures, stocks, ETFs
$0 commission to close options
Pro-grade platform and risk analysis tools

Go to site

Trade $0 commission stocks, ETFs, and options with as little as $1
After-hours trading available
Earn 4.5% interest on uninvested cash with Gold
24/7 customer support

How do similar companies perform?

It's impossible to predict how any stock will perform — and IPOs can be particularly volatile. Looking at the performance of similar companies can help you decide if now is a good time to buy Healthcare Royalty stock.

See how the following stocks are performing, and view details like market capitalization, the price-to-earnings (P/E) ratio, price/earnings-to-growth (PEG) ratio and dividend yield.

Company summary
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
Historical performance
Stock information
- Market capitalization: $121071722496
- P/E ratio: 25.8235
- PEG ratio: 0.8459
- Dividend yield: 0.0427%
Get more detailed information and learn how to buy SNY.US stock
Company summary
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Historical performance
Stock information
- Market capitalization: $21843277824
- P/E ratio: 13.5533
- PEG ratio: 6.2424
- Dividend yield: N/A%
Get more detailed information and learn how to buy BIIB.US stock
Company summary
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Historical performance
Stock information
- Market capitalization: $105118179328
- PEG ratio: 1.0708
- Dividend yield: N/A%
Get more detailed information and learn how to buy VRTX.US stock

Compare trading platforms

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

1 - 10 of 10

Product USFST	Finder Score	Available asset types	Stock trade fee	Minimum deposit	Cash sweep APY	Signup bonus
Tastytrade	Finder score 8.8 Great	Stocks, Options, ETFs, Cryptocurrency, Futures, Treasury Bills	$0	$0	N/A	Get $50-$5,000	Go to site View details	loading Fetching your data...
Robinhood	Finder score 9 Excellent	Stocks, Options, ETFs, Cryptocurrency	$0	$0	4.5%	Get a free stock	Go to site View details	loading Fetching your data...
SoFi Invest®	Finder score 8.2 Great	Stocks, Options, Mutual funds, ETFs, Alternatives	$0	$0	0.02%	Get up to $1,000 in stock	Go to site View details	loading Fetching your data...
OPTO	Finder score 6.2 Standard	Stocks, ETFs	$0	$0	N/A	Earn up to $300	Go to site View details	loading Fetching your data...
eToro	Finder score 8 Great	Stocks, Options, ETFs, Cryptocurrency	$0	$0	4.9%	FINDER EXCLUSIVE: Get a guaranteed $15 bonus and $10 in free crypto	Go to site View details	loading Fetching your data...
Public.com	Finder score 8.6 Great	Stocks, Bonds, Options, ETFs, Cryptocurrency, Alternatives, Treasury Bills, High-yield cash account	$0	$0	4.35%	Get up to $10,000 and transfer fees covered	Go to site View details	loading Fetching your data...
Stash	Finder score 7.4 Great	Stocks, ETFs	$0	$0	0.1%	Get $10 when you sign up and deposit $5	Go to site View details	loading Fetching your data...
Wealthfront	Finder score 9 Excellent	Stocks, ETFs	$0	$500	4.00%	Get $50	Go to site View details	loading Fetching your data...
Zacks Trade	Finder score 7.6 Great	Stocks, Bonds, Mutual funds, ETFs, CDs	$0.01	$250	2.83%	Get up to $500	Go to site View details	loading Fetching your data...
M1 Finance	Finder score 8.2 Great	Stocks, ETFs, Cryptocurrency	$0	$100	4.00%	N/A	Go to site View details	loading Fetching your data...

loading

What is the Finder Score?

The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.

We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.

Read the full Finder Score breakdown

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

More on investing

How to buy FAANG stocks

Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.

Read more…

How to buy soccer stocks

A simple guide to buying stocks in your favorite European soccer team.

Read more…

Inflation stocks

Here are the stocks that benefit from inflation, as well as industries to keep an eye on to reduce the impacts of inflation on your portfolio.

Read more…

Thank you for your feedback!

More resources on Finder

How to buy Absci Corporation stock (Absci Corporation) How to buy Riskified stock (Riskified)

More guides on Finder

Best Stocks for Beginners With Little Money to Invest
These are the stocks to buy when you don’t have much to spend.
Sweep Accounts
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
7 Best Day Trading Apps of 2024
These are the best day trading apps, according to Finder’s comprehensive analysis.
Today’s Best Brokerage Account Bonuses [Signup and Transfer Promos]
Explore the best bonuses for opening a new brokerage account.
5 best stock picking services of 2024
Compare the 5 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
5 Top Graphene Stocks to Invest in Today
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
Ratings methodology for online brokers
Our star ratings for online brokerages are based on how they stack up in nine key categories.
How to invest in the S&P 500 in 2024
What you need to know about investing in the leading indicator for the overall US stock market.
How to Invest $10K
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
5 best ETFs for 2024
Check out the best-performing ETFs so far in 2024.

Ask a question

Click here to cancel reply.

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

How to buy Healthcare Royalty (HCRX) stock when it goes public

Here's everything we know so far about the Healthcare Royalty IPO.

What we know about the Healthcare Royalty IPO

How to buy Healthcare Royalty stock when it starts trading